{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:55:49Z","timestamp":1777953349131,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CDA-AMC, Canada","award":["Grant #C222 360"],"award-info":[{"award-number":["Grant #C222 360"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"DOI":"10.1186\/s13690-026-01895-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:46:55Z","timestamp":1774439215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of risk mitigation measures on oral fluoroquinolone prescribing: a multi-site population-based Canadian cohort study"],"prefix":"10.1186","volume":"84","author":[{"given":"Lisa M.","family":"Lix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audray","family":"St-Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan Maleki","family":"Golandouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donica","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Ronksley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayler Dawn","family":"Scory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Carney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Perras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Canadian Network for Observational Drug Effect Studies (CNODES) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin R.","family":"Dormuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Ronksley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Michael","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid S.","family":"Sketris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","unstructured":"Wierzbi\u0144ski P, Hubska J, Henzler M, Kucharski B, Bie\u015b R, Krzystanek M. Depressive and other adverse CNS effects of fluoroquinolones. Pharmaceuticals (Basel). 2023;16(8):1105. https:\/\/doi.org\/10.3390\/ph16081105","DOI":"10.3390\/ph16081105"},{"issue":"6","key":"1895_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/phar.1761","volume":"36","author":"MR Bidell","year":"2016","unstructured":"Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy. 2016;36(6):679\u201393.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1895_CR3","doi-asserted-by":"publisher","first-page":"NP121","DOI":"10.1177\/1558944717701237","volume":"12","author":"I Berger","year":"2017","unstructured":"Berger I, Goodwin I, Buncke GM. Fluoroquinolone-associated tendinopathy of the hand and wrist: a systematic review and case report. HAND. 2017;12(5):NP121\u20136.","journal-title":"HAND"},{"key":"1895_CR4","doi-asserted-by":"publisher","first-page":"100148","DOI":"10.1016\/j.bbih.2020.100148","volume":"9","author":"N Essali","year":"2020","unstructured":"Essali N, Miller BJ. Psychosis as an adverse effect of antibiotics. Brain Behav Immun Health. 2020;9:100148.","journal-title":"Brain Behav Immun Health"},{"issue":"2","key":"1895_CR5","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1002\/pds.70081","volume":"34","author":"T Lasys","year":"2025","unstructured":"Lasys T, Santa-Ana-Tellez Y, Siiskonen SJ, Groenwold RHH, Gardarsdottir H. Impact of pharmacovigilance interventions targeting fluoroquinolones on antibiotic use in the Netherlands and the United Kingdom. Pharmacoepidemiol Drug Saf. 2025;34(2):e70081.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1895_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamainternmed.2021.1154","volume":"181","author":"PT Tran","year":"2021","unstructured":"Tran PT, Antonelli PJ, Hincapie-Castillo JM, Winterstein AG. Association of US Food and Drug Administration removal of indications for use of oral quinolones with prescribing trends. JAMA Intern Med. 2021;181(6):808\u201316.","journal-title":"JAMA Intern Med"},{"key":"1895_CR7","unstructured":"Health Canada. Summary Safety Review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html. Accessed 20 Sept 2025."},{"key":"1895_CR8","unstructured":"Health Canada. Summary Safety Review - Fluoroquinolones - Assessing the potential risk of aneurysm (a balloon-like bulge) and dissection (a separation or tear in the layers of the wall) of the aorta (a major blood vessel) https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SSR00226. Accessed 20 Sept 2025."},{"key":"1895_CR9","unstructured":"European Medicines Agency (EMA). Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics https:\/\/www.ema.europa.eu\/en\/news\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone. Accessed 20 Sept 2025."},{"key":"1895_CR10","unstructured":"European Medicines Agency (EMA). Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects https:\/\/www.ema.europa.eu\/en\/news\/fluoroquinolone-antibiotics-reminder-measures-reduce-risk-long-lasting-disabling-potentially. Accessed 20 Sept 2025."},{"key":"1895_CR11","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). MHRA introduces new restrictions for fluoroquinolone antibiotics https:\/\/www.gov.uk\/government\/news\/mhra-introduces-new-restrictions-for-fluoroquinolone-antibiotics. Accessed 20 Sept 2025."},{"key":"1895_CR12","unstructured":"Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects. Accessed 20 Sept 2025."},{"issue":"4","key":"1895_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40264-023-01286-4","volume":"46","author":"NF Ly","year":"2023","unstructured":"Ly NF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P, et al. Impact of European Union label changes for fluoroquinolone-containing medicinal products for systemic and inhalation use: post-referral prescribing trends. Drug Saf. 2023;46(4):405\u201316.","journal-title":"Drug Saf"},{"issue":"3","key":"1895_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4212\/cjhp.v68i3.1457","volume":"68","author":"SM Cadarette","year":"2015","unstructured":"Cadarette SM, Wong L. An introduction to health care administrative data. Can J Hosp Pharm. 2015;68(3):232\u20137.","journal-title":"Can J Hosp Pharm"},{"issue":"7","key":"1895_CR15","doi-asserted-by":"publisher","first-page":"e0015121","DOI":"10.1128\/AAC.00151-21","volume":"65","author":"DJ Buehrle","year":"2021","unstructured":"Buehrle DJ, Wagener MM, Clancy CJ. Outpatient fluoroquinolone prescription fills in the United States, 2014 to 2020: assessing the impact of Food and Drug Administration safety warnings. Antimicrob Agents Chemother. 2021;65(7):e0015121.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1895_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cmi.2021.10.013","volume":"28","author":"BD Knight","year":"2022","unstructured":"Knight BD, Shurgold J, Smith G, MacFadden DR, Schwartz KL, Daneman N, et al. The impact of COVID-19 on community antibiotic use in Canada: an ecological study. Clin Microbiol Infect. 2022;28(3):426\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"1895_CR17","doi-asserted-by":"publisher","unstructured":"Domingues M, Torre C, Guerreiro JP, Barata P, Correia-Neves M, Rocha J, Sepodes B, Teixeira Rodrigues A. COVID-19 pandemic and the quality of antibiotic use in primary care: an interrupted time-series study. Int J Qual Health Care. 2023;35(2):mzad014. https:\/\/doi.org\/10.1093\/intqhc\/mzad014.","DOI":"10.1093\/intqhc\/mzad014"},{"issue":"2","key":"1895_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jac\/dkae440","volume":"80","author":"F Hamilton","year":"2025","unstructured":"Hamilton F, Darley E, Arnold K, MacGowan A. Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023. J Antimicrob Chemother. 2025;80(2):518\u201327.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1895_CR19","doi-asserted-by":"publisher","first-page":"e0296048","DOI":"10.1371\/journal.pone.0296048","volume":"18","author":"H Kari","year":"2023","unstructured":"Kari H, R\u00e4tt\u00f6 H, Saastamoinen L, Koskinen H. Outpatient antibiotic prescribing during the first two years of the COVID-19 pandemic: a nationwide register-based time series analysis. PLoS One. 2023;18(12):e0296048.","journal-title":"PLoS One"},{"issue":"1","key":"1895_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12879-021-06467-z","volume":"21","author":"A St-Jean","year":"2021","unstructured":"St-Jean A, Chateau D, Dahl M, Ernst P, Daneman N, Sketris IS, et al. Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study. BMC Infect Dis. 2021;21(1):733.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1895_CR21","first-page":"e134","volume":"6","author":"S Suissa","year":"2012","unstructured":"Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med. 2012;6(4):e134-140.","journal-title":"Open Med"},{"issue":"Suppl 1","key":"1895_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/pds.4936","volume":"29","author":"RW Platt","year":"2020","unstructured":"Platt RW, Henry DA, Suissa S. The Canadian Network for Observational Drug Effect Studies (CNODES): reflections on the first eight years, and a look to the future. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 1):103\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1895_CR23","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.2147\/COPD.S226324","volume":"14","author":"P Ernst","year":"2019","unstructured":"Ernst P, Dahl M, Chateau D, Daneman N, Quail J, Sketris IS, et al. Comparative effectiveness of fluoroquinolone antibiotic use in uncomplicated acute exacerbations of COPD: a multi-cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:2939\u201346.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"14\u201315","key":"1895_CR24","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/sim.4780111406","volume":"11","author":"SL Zeger","year":"1992","unstructured":"Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11(14\u201315):1825\u201339.","journal-title":"Stat Med"},{"key":"1895_CR25","volume-title":"Generalized, linear, and mixed models","author":"CE McCulloch","year":"2001","unstructured":"McCulloch CE, Searle SR. Generalized, linear, and mixed models. New York: Wiley; 2001."},{"issue":"1","key":"1895_CR26","first-page":"348","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348\u201355.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1895_CR27","doi-asserted-by":"publisher","first-page":"e070031","DOI":"10.1136\/bmjopen-2022-070031","volume":"14","author":"S Zeitouny","year":"2024","unstructured":"Zeitouny S, McGrail K, Tadrous M, Wong ST, Cheng L, Law M. Impact of the COVID-19 pandemic on prescription drug use and costs in British Columbia: a retrospective interrupted time series study. BMJ Open. 2024;14(1):e070031.","journal-title":"BMJ Open"},{"issue":"3","key":"1895_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"2","key":"1895_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193\u2013206.","journal-title":"Psychol Methods"},{"key":"1895_CR30","doi-asserted-by":"publisher","unstructured":"Hamilton A, Poleon S, Cherian J, Cosgrove S, Laxminarayan R, Klein E. COVID-19 and outpatient antibiotic prescriptions in the United States: a county-level analysis. Open Forum Infect Dis. 2023;10(3):ofad096. https:\/\/doi.org\/10.1093\/ofid\/ofad096.","DOI":"10.1093\/ofid\/ofad096"},{"issue":"4","key":"1895_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.cmi.2024.12.005","volume":"31","author":"S Tsuzuki","year":"2025","unstructured":"Tsuzuki S, Koizumi R, Asai Y, Ohmagari N. Trends in antimicrobial consumption: long-term impact of the COVID-19 pandemic. Clin Microbiol Infect. 2025;31(4):594\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"49","key":"1895_CR32","doi-asserted-by":"publisher","first-page":"e2411919121","DOI":"10.1073\/pnas.2411919121","volume":"121","author":"EY Klein","year":"2024","unstructured":"Klein EY, Impalli I, Poleon S, Denoel P, Cipriano M, Van Boeckel TP, et al. Global trends in antibiotic consumption during 2016\u20132023 and future projections through 2030. Proc Natl Acad Sci USA. 2024;121(49):e2411919121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1895_CR33","doi-asserted-by":"publisher","first-page":"e2136662","DOI":"10.1001\/jamanetworkopen.2021.36662","volume":"4","author":"A Sankar","year":"2021","unstructured":"Sankar A, Swanson KM, Zhou J, Jena AB, Ross JS, Shah ND, et al. Association of fluoroquinolone prescribing rates with black box warnings from the US Food and Drug Administration. JAMA Netw Open. 2021;4(12):e2136662.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1895_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cmi.2019.10.016","volume":"26","author":"N Daneman","year":"2020","unstructured":"Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, et al. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. Clin Microbiol Infect. 2020;26(5):613\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"1895_CR35","unstructured":"Public Health Agency of Canada. Tackling antimicrobial resistance and antimicrobial use: a pan-Canadian framework for action. Ottawa, ON: 2017. https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/drugs-health-products\/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.html."},{"key":"1895_CR36","unstructured":"Public Health Agency of Canada. Pan-Canadian action plan on antimicrobial resistance. Ottawa, ON: 2023. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/drugs-health-products\/pan-canadian-action-plan-antimicrobial-resistance.html."},{"issue":"1","key":"1895_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12875-023-02223-1","volume":"25","author":"GE Kasse","year":"2024","unstructured":"Kasse GE, Humphries J, Cosh SM, Islam MS. Factors contributing to the variation in antibiotic prescribing among primary health care physicians: a systematic review. BMC Prim Care. 2024;25(1):8.","journal-title":"BMC Prim Care"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-026-01895-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:03:33Z","timestamp":1777907013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13690-026-01895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1186\/s13690-026-01895-2","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research ethics board approvals were obtained at each participating institution: the Conjoint Health Research Ethics Board at the University of Calgary (Alberta); the Clinical Research Ethics Board at the University of British Columbia (British Columbia); the Health Research Ethics Board at the University of Manitoba (Manitoba); the Health Sciences Research Ethics Board at Dalhousie University (Nova Scotia); and the Biomedical Research Ethics Board at the University of Saskatchewan (Saskatchewan), except at ICES in Ontario, where research ethics board approval was not legally required. Informed consent was not required because this study used anonymized administrative data. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}